RNLX Live signaler | Maksimer profitt med Getagraph.com

SELG 115417 min ago

@ $1.190

Utstedt: 14 feb 2024 @ 21:54

Avkastning: -41.17%

Forrige signal: feb 14 - 19:31

Forrige signal: Kjøp

Avkastning: 3.48 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	216 840
Gjennomsnittsvolum	1.95M
Markedsverdi	47.76M
EPS	$-0.110 ( 2023-11-14 )
Neste inntjeningsdato	( $-0.0800 ) 2024-06-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.780
ATR14	$0.00900 (1.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-24	Icahn School Of Medicine At Mount Sinai	Buy	9 360 374	Ordinary Shares
2023-11-20	Coste Catherine	Buy	95 000	Employee Stock Option (right to buy)
2023-11-20	Levangie Daniel J	Buy	95 000	Employee Stock Option (right to buy)
2023-11-20	Parikh Chirag R.	Buy	95 000	Employee Stock Option (right to buy)
2023-11-20	Mills Christopher	Buy	95 000	Employee Stock Option (right to buy)

INSIDER POWER
84.31
Last 27 transactions
Buy: 12 713 670 \| Sell: 1 641 743

Volum Korrelasjon

Lang: -0.35 (neutral)

Kort: -0.28 (neutral)

Signal:(42.915) Neutral

Renalytix AI plc Korrelasjon

10 Mest positive korrelasjoner
PUCK	0.925
NVCN	0.921
TWLV	0.92
TWCB	0.92
KSICU	0.919
GXII	0.918
OVID	0.917
UBFO	0.916
TBLA	0.915
KVSA	0.914

10 Mest negative korrelasjoner
AMGN	-0.943
NAKD	-0.921
CYTO	-0.921
AHPI	-0.913
HCAQ	-0.909
PROC	-0.905
LAWS	-0.905
THMA	-0.896
PCSA	-0.894
LSAQ	-0.892

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Renalytix AI plc Korrelasjon - Valuta/Råvare

-0.29
( neutral )

-0.07
( neutral )

0.00
( neutral )

-0.34
( neutral )

0.42
( neutral )

0.36
( neutral )

Renalytix AI plc Økonomi

Annual	2023
Omsetning:	$3.40M
Bruttogevinst:	$701 000 (20.60 %)
EPS:	$-1.120

FY	2023
Omsetning:	$3.40M
Bruttogevinst:	$701 000 (20.60 %)
EPS:	$-1.120

FY	2022
Omsetning:	$2.97M
Bruttogevinst:	$918 000 (30.91 %)
EPS:	$-1.560

FY	2021
Omsetning:	$1.49M
Bruttogevinst:	$633 000 (42.45 %)
EPS:	$-0.860

Financial Reports:

No articles found.

Renalytix AI plc

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.